Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. Its subsidiaries include SkinJect, Inc, and Medicus Pharma Inc. The Company’s wholly owned subsidiary, SkinJect, Inc (SkinJect), is focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumor cells. The Company’s wholly owned subsidiaries are focused on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. The Company investigates opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The Company is actively exploring expanding its drug development pipeline through qualified and accretive acquisitions and partnerships.
BörsenkürzelMDCXW
Name des UnternehmensMedicus Pharma Ltd
IPO-datumOct 11, 2023
CEODr. Raza Bokhari, M.D.
Anzahl der mitarbeiter- -
WertpapierartCompany Warrant
Geschäftsjahresende- -
Addresse100 King Street West
StadtTORONTO
BörseNASDAQ Capital Market Consolidated
LandCanada
PostleitzahlM5X 1A4
Telefon17323003046
Websitehttps://medicuspharma.com/
BörsenkürzelMDCXW
IPO-datumOct 11, 2023
CEODr. Raza Bokhari, M.D.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten